AIM
MYGN icon

Acrospire Investment Management’s Myriad Genetics MYGN Stock Holding History

Acrospire Investment Management’s Portfolio MYGN Stock Details MYGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-47
Closed -$1K – 914
2017
Q2 		$1K Sell
47
-500
-91% -$10.6K ﹤0.01% 2100
2017
Q1 		$11K Sell
547
-4,558
-89% -$80.8K 0.01% 1844
2016
Q4 		$85K Sell
5,105
-5,295
-51% -$95.8K 0.04% 1049
2016
Q3 		$214K Buy
10,400
+5,100
+96% +$129K 0.14% 128
2016
Q2 		$162K Buy
5,300
+2,400
+83% +$83.4K 0.12% 164
2016
Q1 		$109K Buy
+2,900
New +$109K 0.08% 270

Other funds holding MYGN

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
FCM
Frontier Capital Management Boston, Massachusetts $9.73B AUM 55.65% 1-Year Est. Return
CCM
Camber Capital Management Boston, Massachusetts $1.07B AUM 8.19% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Acrospire Investment Management's MYGN Position: Q3 2017 in Review

Acrospire Investment Management sold out of Myriad Genetics (MYGN) in Q3 2017, closing a stake of 47 shares — an estimated $1K sold.

Acrospire Investment Management first reported a position in MYGN in Q1 2016 and held it in 6 quarters. The position peaked at $214K in Q3 2016. 220 funds tracked by Wall St. Rank hold MYGN as of Q3 2017.

  • Acrospire Investment Management reported no remaining Myriad Genetics position as of Q3 2017 after selling out during the quarter.
  • Acrospire Investment Management sold 47 Myriad Genetics shares in Q3 2017, an estimated $1K.
  • Acrospire Investment Management first reported a position in Myriad Genetics in Q1 2016 and held it in 6 quarters.
  • Acrospire Investment Management's Myriad Genetics position peaked at $214K in Q3 2016.
  • 220 funds tracked by Wall St. Rank held Myriad Genetics as of Q3 2017.

Based on Acrospire Investment Management's 13F filing for Q3 2017, filed 26 Oct 2017.